OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Somerset, N.J. – Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the launch of its FastChain™ service, for greater speed, flexibility and efficiency in the management of global clinical supplies. Based upon the company’s demand led supply model, FastChain is a continuous GMP approach to clinical supply management that decouples primary packaging from secondary packaging, and enables the final assembly, labeling and distribution of clinical supplies on a regional basis. This approach reduces the need to pre-package bulk supplies far in advance of the study start, creates the ability to pool supplies across protocols, and has the potential to reduce clinical waste from upwards of 200% or more to less than 20%. Investigator sites will receive only the clinical supplies they need to meet actual patient demand within a matter of days rather than weeks. Furthermore, mid-study changes such as revised dosing schedules or the addition of countries and clinical sites will be easy to accommodate for FastChain customers. “Catalent is already performing global demand led supply services on behalf of a major pharmaceutical customer and will now introduce its unique FastChain service to bring demand led supply to the broader industry,” stated Wetteny Joseph, President, Catalent Clinical Supply Services. “We have seen significant interest from companies of all sizes who are looking for more flexible and innovative solutions to get to the clinic faster.” Catalent will continue to make significant investments in its facilities worldwide to include specialized packaging lanes, and integrated systems and processes to support demand led studies and will make the FastChain service available for both ambient and cold chain studies on a global basis. About Catalent Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com